Core Viewpoint - Beilu Pharmaceutical (300016.SZ) has developed a proprietary traditional Chinese medicine, Jiuwei Zhenxin Granules, which has been approved by the National Medical Products Administration for the treatment of generalized anxiety disorder and is included in the medical insurance catalog, making it a unique product of the company [1] Group 1 - Jiuwei Zhenxin Granules is a self-developed innovative traditional Chinese medicine by the company [1] - The product is a pure traditional Chinese medicine formulation approved for treating generalized anxiety disorder [1] - It is also a medical insurance product, indicating its significance in the healthcare market [1]

股票代码：300016 股票简称：北陆药业 公告编号：2025-117 北京北陆药业股份有限公司 1 关于召开2025年第四次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）于2025年10月29日在 巨潮资讯网发布了《关于召开2025年第四次临时股东会的通知》，为进一步 保护投资者的合法权益，方便公司股东行使股东会表决权，现将股东会的有 关事项提示如下： 一、召开会议的基本情况 1、股东会届次：2025年第四次临时股东会 2、股东会的召集人：董事会 3、会议召开的合法、合规性：公司第九届董事会第五次会议审议通过了 《关于召开2025年第四次临时股东会的议案》，本次股东会会议的召开符合有 关法律、行政法规、部门规章、规范性文件和《公司章程》等规定。 4、会议时间： （1）现场会议时间：2025年11月13日14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为2025年11月13日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所 互 ...

Group 1 - The core viewpoint of the news is that Beilu Pharmaceutical has shown a significant increase in stock price and positive financial performance indicators, indicating potential growth and investor interest [1][2]. Group 2 - As of November 12, Beilu Pharmaceutical's stock price increased by 2.05% to 8.97 CNY per share, with a total market capitalization of 5.049 billion CNY [1]. - The company has experienced a year-to-date stock price increase of 45.85%, with a recent 5-day increase of 2.99% and a 20-day increase of 2.28%, although it has seen a decline of 8.38% over the past 60 days [1]. - Beilu Pharmaceutical's main business segments include contrast agents (63.33% of revenue), traditional Chinese medicine (22.09%), and diabetes medications (12.75%) [1]. Group 3 - For the period from January to September 2025, Beilu Pharmaceutical achieved operating revenue of 873 million CNY, representing a year-on-year growth of 19.59%, and a net profit attributable to shareholders of 44.177 million CNY, reflecting an 81.10% increase [2]. - The company has distributed a total of 369 million CNY in dividends since its A-share listing, with 59.03 million CNY distributed over the past three years [3].

Group 1 - Digital Zhengtong's subsidiary Baoding Jindi won a bid for a smart water project in Jinan, with a total contract value of 109 million yuan, of which Baoding Jindi's share is approximately 77 million yuan [1] - Lingzhi Software plans to acquire 100% equity of Kaimiride through a combination of cash and stock issuance, with the final transaction price yet to be determined [1] - Tianjin Port's subsidiary plans to transfer 60% equity of China Railway Storage and Transportation, with an estimated value of 37.54 million yuan for the entire equity [2] Group 2 - New Wufeng reported a 56.97% year-on-year increase in pig sales in October, selling 610,000 pigs [3] - New Peng Co. announced a joint investment of approximately 15 million USD with Jabil to build a battery storage box project in Thailand [4] - Maiwei Bio received approval for a clinical trial of its 9MW3811 injection for pathological scars [6] Group 3 - Jiangsu Sopo completed maintenance and resumed production of its methanol and acetic acid facilities [8] - Luoniushan reported a 24.65% year-on-year increase in pig sales revenue in October, totaling 116 million yuan [9][10] - Zhongbei Communication signed a 1 billion yuan comprehensive computing service framework agreement with Xiamen Hongxin Electronics [11] Group 4 - Huayang New Materials announced the resignation of its general manager, Wu Yuehua [12] - Zhongxin Co. used 50 million yuan of idle funds to purchase structured deposits with expected annual returns between 0.55% and 2.05% [14] - Huajian Group's subsidiary signed a construction engineering design contract worth 96.54 million yuan [16] Group 5 - Jianyou Co. received FDA approval for a new production site for its injectable drug [17] - Beilu Pharmaceutical obtained a drug registration certificate for its iodine mepivacaine injection, which is included in the national medical insurance catalog [19] - *ST Yuancheng's stock will be suspended due to falling below the market cap threshold for delisting [20] Group 6 - Xiantan Co. reported a 9.3% year-on-year increase in chicken product sales revenue in October, totaling 503 million yuan [21] - Huanxu Electronics reported an 8.93% year-on-year decrease in consolidated revenue for October, amounting to 5.598 billion yuan [23] - Yisheng Co. reported a 22.97% year-on-year decrease in white feather chicken seed sales revenue in October [25] Group 7 - Yuandong Bio initiated a Phase I/II clinical trial for its ADC drug YLSH003 targeting advanced solid tumors [25] - Xiaoming Co. reported a 34.89% year-on-year decrease in chicken product sales revenue in October [26] - Nanjiao Food reported a 5.27% year-on-year decrease in consolidated revenue for October, totaling 235 million yuan [28] Group 8 - Chuangye Huikang announced a potential change in control, leading to a temporary stock suspension [30] - Tangrenshen reported a 17.91% year-on-year decrease in pig sales revenue in October, totaling 828 million yuan [32][33] - Wancheng Group plans to distribute a cash dividend of 1.5 yuan per 10 shares to shareholders [34] Group 9 - Kangguan Technology plans to distribute a cash dividend of 3.6 yuan per 10 shares to shareholders [36] - Shoudu Online's executive plans to reduce holdings of up to 19,400 shares [38] - Maolai Optical received approval for the issuance of convertible bonds [40] Group 10 - Jinkai New Energy plans to distribute a cash dividend of 0.1 yuan per share to shareholders [41] - Tianchen Medical raised the upper limit for share repurchase to 70 yuan per share [42] - Tianmu Lake used 38 million yuan of idle funds to purchase structured deposits [43]

Core Points - Beilu Pharmaceutical announced the convening of the 9th Board of Directors' fourth meeting on September 25, 2025, and the third extraordinary shareholders' meeting on October 14, 2025, to review the proposal for changing registered capital and amendments [1] - The "Beilu Convertible Bonds" began conversion on June 11, 2021, and triggered conditional redemption on July 14, 2025 [1] - The company decided to redeem all "Beilu Convertible Bonds" at face value plus accrued interest, with trading ceasing on July 31, 2025, and conversion stopping on August 5, 2025 [1] - A total of 71,017,267 shares of "Beilu Pharmaceutical" were converted from the bonds, increasing the total share capital from 491,855,896 shares to 562,873,163 shares [1] - The registered capital changed from 491,855,896 yuan to 562,873,163 yuan, and the company completed the business registration change procedures [1]

Core Viewpoint - Beilu Pharmaceutical has received approval from the National Medical Products Administration for the registration certificate of Iodinated Contrast Agent Injection [2] Company Summary - Beilu Pharmaceutical announced the receipt of the drug registration certificate for Iodinated Contrast Agent Injection on November 10 [2]

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) has received approval from the National Medical Products Administration for the iodine-based contrast agent, Iodine Meperidine Injection, which is expected to enhance its product portfolio in the imaging diagnostics market [1] Group 1: Product Approval - The Iodine Meperidine Injection is a non-ionic monomer X-ray contrast agent used for various medical imaging diagnostics [1] - The product has been included in the National Medical Insurance Category B directory, indicating its significance in the healthcare system [1] Group 2: Market Performance - Sales of iodine-based contrast agents have been steadily increasing in the Chinese market in recent years, reflecting a growing demand for imaging diagnostics [1] - The approval of Iodine Meperidine Injection will further enrich the company's offerings in the iodine contrast agent segment [1] Group 3: Future Plans - The company plans to actively prepare for the launch of the new product following its approval [1]

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) has received approval from the National Medical Products Administration for the iodine-based contrast agent, Iodine Meper, which is expected to drive significant sales growth in the coming years [1] Group 1: Product Details - Iodine Meper is a non-ionic monomer X-ray contrast agent developed by Italy's Bracco, characterized by excellent physicochemical properties, including the lowest osmotic pressure and lower viscosity compared to similar agents at the same concentration [1] - The product is stable in its physicochemical properties and does not require the addition of chelating agents [1] - Indications for Iodine Meper include intravenous urography, CT scans, conventional angiography, and various forms of vascular imaging for both adults and children [1] Group 2: Market Potential - Iodine Meper has been included in the National Medical Insurance Class B directory, enhancing its market accessibility [1] - According to data from Minet, sales in China's three major terminal markets have been growing at double-digit rates, with projected sales exceeding 1.1 billion yuan in 2024, representing a year-on-year growth of approximately 32% [1] - In the first quarter of 2025, sales are expected to surpass 300 million yuan, with a year-on-year growth of about 39% [1]

Core Viewpoint - Beilu Pharmaceutical has received approval from the National Medical Products Administration for the iodine-based contrast agent, Iodixanol Injection, which is expected to enhance its product portfolio in the imaging agent market [1] Group 1: Product Details - Iodixanol Injection is developed by Italian company Bracco and is classified as a non-ionic monomer X-ray contrast agent [1] - The product exhibits superior physicochemical properties, having the lowest osmotic pressure and lower viscosity compared to similar non-ionic monomer X-ray contrast agents at the same concentration [1] - Iodixanol Injection is stable in its physicochemical properties and does not require the addition of chelating agents [1] Group 2: Indications - The indications for Iodixanol Injection include intravenous urography (for adults, including those with renal impairment or diabetes), CT imaging (trunk), conventional angiography, arterial DSA, cardiovascular imaging (for both adults and children), selective coronary angiography, interventional coronary angiography, fistula imaging, duct imaging, lacrimal duct imaging, and salivary duct imaging [1]

Core Viewpoint - Northland Pharmaceutical has received approval from the National Medical Products Administration for the iodine-based contrast agent, Iodine Meperidine Injection, which is expected to drive significant sales growth in the coming years [1] Company Summary - Northland Pharmaceutical has announced the approval of Iodine Meperidine Injection, developed by Italy's Bracco, which is a non-ionic monomer X-ray contrast agent [1] - The product exhibits superior physicochemical properties, having the lowest osmotic pressure and lower viscosity compared to similar agents at the same concentration, and does not require the addition of chelating agents [1] - The indications for Iodine Meperidine Injection include intravenous urography, CT scans, conventional angiography, and various other imaging procedures for both adults and children [1] Industry Summary - Iodine Meperidine Injection has been included in the National Medical Insurance Category B directory, indicating its significance in the healthcare market [1] - According to data from Minet, sales in China's three major terminal markets have been growing at a double-digit rate, with projected sales exceeding 1.1 billion yuan in 2024, representing a year-on-year growth of approximately 32% [1] - In the first quarter of 2025, sales are expected to surpass 300 million yuan, with a year-on-year growth of about 39% [1]